Amorphical

Company Overview

Snapshot

Founded in July 2004 by Yossi Ben, Amorphical operates with 11–50 employees. The company has raised $28.3 million across 6 funding rounds from 2 investors. In September 2025, Amorphical announced positive interim results from an ongoing clinical trial for Crohn's disease.

Business overview

Amorphical is a biotechnology company focused on developing and manufacturing natural-based medicines and dietary supplements. Its core technology involves stabilizing a rare natural form of calcium, amorphous calcium carbonate, to create nanometric substances that improve calcium absorption and manage body acidity. The company's products, including DENSITY, AMOR-18, pHGastrilex, pHdirect, and pHkids, are designed to enhance health, repair bone deficiencies, and treat various diseases, serving markets in Health Tech & Life Sciences, Pharmaceuticals, and Biotechnology.

Strategic signal

Amorphical is demonstrating significant clinical progress, with positive interim results from its ongoing Crohn's disease trial announced in September 2025. This advancement highlights the potential of its nano-amorphous mineral-based pharmacologic agents and signals strong validation for its therapeutic approach in addressing chronic inflammatory conditions, which could attract further investment and strategic partnerships in the pharmaceutical sector.

Company Intelligence Q&A

What was the most recent leadership appointment at Amorphical?

In September 2025, Amorphical announced the appointment of Eden Ben as CEO, as the company advances its regulatory pathway for nano-amorphous mineral-based therapeutics.

What clinical trial milestone did Amorphical achieve in November 2025?

In November 2025, Amorphical announced the enrollment of the first patient in its Phase 2 clinical trial for nano-amorphous mineral-based therapy in Stage IV pancreatic cancer patients.

What long-term data presentation is Amorphical planning for its Crohn's disease trial?

In February 2026, Amorphical announced plans to present long-term data from its Phase 2 trial in Crohn's disease at the 21st Congress of ECCO.

What was the outcome of Amorphical's calcium absorption trial in March 2014?

In March 2014, Amorphical reported successful results from its calcium absorption trial.

What was the outcome of Amorphical's COVID-19 clinical trial in January 2022?

In January 2022, Amorphical announced outstanding preliminary results from a clinical trial treating moderate-to-severe COVID-19 patients.